Advertisement
Product › Details
MVA-BN® filovirus (Ebola and Marburg) vaccine
Status | 2014-10-22 development existent | |
Organisation | Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) | |
Group | Bavarian Nordic (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for vaccine_o
- [1] Bavarian Nordic A/S. (6/12/20). "Press Release: Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen". Copenhagen....
- [2] Valneva S.E.. (1/9/20). "Press Release: Valneva Expands its Commercial Operations with the Opening of its French Commercial Office". Saint-Herblain....
- [3] Themis Bioscience GmbH. (10/29/19). "Press Release: Themis Bioscience and CEPI Announce Initiation of Phase 1 Clinical Trial with Lassa Fever Vaccine". Vienna & Oslo....
- [4] Themis Bioscience GmbH. (6/4/19). "Press Release: CEPI Awards up to US$21 Million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development". Vienna & Oslo....
- [5] Bavarian Nordic A/S. (3/16/18). "Press Release: Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus". Copenhagen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top